Company news

CSL Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Research and Development Investor Briefing 2019

December 3, 2019

CSL Full Year Statutory Accounts for the Year Ended 30/06/19

August 13, 2019

Update on CSL transition to own distributor model in china

June 20, 2019

Half Year Results Analyst Presentation

February 12, 2019

Appendix 4D and Half Year Accounts

February 12, 2019

CSL R&D Investor Briefing

December 4, 2018

Full Year Results Announcement

August 14, 2018

Full Year Statutory Accounts

August 14, 2018

CSL Lifts Profit Guidance

May 17, 2018

CEOs AGM Presentation

October 17, 2017

New Debt Facilities

October 4, 2017

FDA Approves Privigen for CIDP Indication

September 14, 2017

CSL Behring Acquires US Biotech Company Calimmune

August 27, 2017

2017 FY Results Announcement and Analysts Presentation

August 15, 2017

Appendix 4E, Directors Report and Financial Statements

August 15, 2017

CSL Completes Acquisition of Majority Stake in Ruide

August 2, 2017

CSL Response to Patent Infringement Complaint

July 9, 2017

FDA approves CSL Berhings HAEGARDA

June 22, 2017

CSL to Acquire Majority Stake in Chinese Plasma Fractionator

June 12, 2017

Half Year Results Release

February 14, 2017

Half Year Results Analysts Presentation

February 14, 2017

FY2017 Profit Upgrade

January 18, 2017

AFSTYLA (rFVIII-Single Chain) European Commission Approval

January 8, 2017

Positive Results from CSL112 Phase 2b Trial

November 15, 2016

Afstyla CHMP Recommendation

November 13, 2016

FDA Accepts BLA for Hereditary Angioedema Therapy

August 29, 2016

2016 FY Results Announcements and Analysts Briefing

August 16, 2016

AFSTYLA (rFVIII-Single Chain) FDA approval

May 25, 2016

Flucelvax Quadrivalent (Influenza Vaccine) - FDA Approval

May 23, 2016

IDELVION(R) (rFIX-FP) - European Commission Approval

May 11, 2016

CSL to acquire Novartis influenza vaccine business

March 30, 2016

Chairman`s Address to Shareholders

March 30, 2016

Recombinant Technologies

March 30, 2016

Chairmans and MDs address to shareholders

March 30, 2016

Announcement of buy-back

March 30, 2016

Appointment of Paul Perreault as Executive Director

March 30, 2016

New US$500 million Private Placement

March 30, 2016

Full Year Results, Appendix 4E and Analysts Presentation

March 30, 2016

CSL Settles US Class Action and Updated Profit Guidance

March 30, 2016

Half Yearly Report and Accounts

March 30, 2016

Appendix 4E, FY Results and Analysts Presentation

March 30, 2016

Changes relating to buy-back - Appendix 3D

March 22, 2016

IDELVION(R) (rFIX-FP) - FDA approval

March 6, 2016

IDELVION(R) (rFIX-FP) - CHMP recommendation

February 28, 2016

Half Year Accounts

February 15, 2016

Announcement of buy-back - Appendix 3C

February 11, 2016

US FDA Accepts for Review rFVIII BLA

February 10, 2016

Update on Novartis Influenza Vaccine Acquisition

February 10, 2016

Response to an ASX Query

February 10, 2016

Placement

February 10, 2016

← Newer news releases · Older news releases →

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 82 decks. Every deck is listed under its year.